<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a highly malignant B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> characterized by chromosomal translocations that constitutively activate the c-myc oncogene </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells are resistant to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and do not accumulate ubiquitin conjugates in response to otherwise toxic doses of inhibitors of the proteasome </plain></SENT>
<SENT sid="2" pm="."><plain>Deubiquitinating enzymes and the cytosolic subtilisin-like protease tripeptidylpeptidase II are upregulated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, and could be rapidly induced by the overexpression of c-myc in <z:mpath ids='MPATH_458'>normal</z:mpath> B cells carrying <z:chebi fb="67" ids="50114">oestrogen</z:chebi>-driven recombinant Epstein-Barr virus </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was induced by inhibiting tripeptidylpeptidase II, suggesting that the activity of this protease may be required for the survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>We thus show that there is a regulatory link between c-myc activation and changes in proteolysis that may affect <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
</text></document>